Here's what most people miss about Eli Lilly's $3.8B vaccine acquisitions

Here's what most people miss about Eli Lilly's $3.8B vaccine acquisitions. It's not just about new drugs; it's a strategic pivot into infectious diseases and acquiring platform technologies.

This signals long-term confidence in the vaccine market beyond COVID. For Indian biopharma, this means increased global interest in our vaccine R&D and manufacturing capabilities. Expect more M&A and partnership opportunities as big pharma diversifies its pipeline.

https://medcitynews.com/2026/05/eli-lilly-vaccine-acquisitions-infectious-disease-curevo-limmatech-shingles-staph-infection-ebv-lly/